相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study
Gordon Lowe et al.
DIABETES (2014)
Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis
Aart C. Strang et al.
ATHEROSCLEROSIS (2013)
Impact of inflammatory biomarkers on relation of high density lipoprotein-cholesterol with incident coronary heart disease: Cardiovascular Health Study
David M. Tehrani et al.
ATHEROSCLEROSIS (2013)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: CATALYTIC RECEPTORS
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Inflammatory Markers and Risk of Type 2 Diabetes A systematic review and meta-analysis
Xia Wang et al.
DIABETES CARE (2013)
Targeting Interleukin-6 in Rheumatoid Arthritis
Md Yuzaiful Md Yusof et al.
DRUGS (2013)
Components of the Interleukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness
Thomas W. Weiss et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2013)
IL-6 Regulates Mcl-1L Expression through the JAK/PI3K/Akt/CREB Signaling Pathway in Hepatocytes: Implication of an Anti-Apoptotic Role during Liver Regeneration
Chia-Hung Chou et al.
PLOS ONE (2013)
Therapeutic Targeting of the Interleukin-6 Receptor
Toshio Tanaka et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in Mice
Harald Schuett et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2012)
The role of tocilizumab in the management of rheumatoid arthritis
Zoe Ash et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2012)
Hitting a complex target: an update on interleukin-6 trans-signalling
Georg H. Waetzig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
IL-6 Trans-Signaling via the Soluble IL-6 Receptor: Importance for the Pro-Inflammatory Activities of IL-6
Stefan Rose-John
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2012)
Tocilizumab Treatment Decreases Circulating Myeloid Dendritic Cells and Monocytes, 2 Components of the Myeloid Lineage
Christophe Richez et al.
JOURNAL OF RHEUMATOLOGY (2012)
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies
Nadeem Sarwar et al.
LANCET (2012)
The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis
Daniel I. Swerdlow et al.
LANCET (2012)
A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis
A. D. Protogerou et al.
ATHEROSCLEROSIS (2011)
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Juergen Scheller et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2011)
Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding
Christoph Garbers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Inhibition of Classic Signaling Is a Novel Function of Soluble Glycoprotein 130 (sgp130), Which Is Controlled by the Ratio of Interleukin 6 and Soluble Interleukin 6 Receptor
Christoph Garbers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Contribution of vascular cell-derived cytokines to innate and inflammatory pathways in atherogenesis
Harald Loppnow et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2011)
Atherosclerosis: current pathogenesis and therapeutic options
Christian Weber et al.
NATURE MEDICINE (2011)
Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells
Helga Ellingsgaard et al.
NATURE MEDICINE (2011)
Effects of Disturbed Flow on Vascular Endothelium: Pathophysiological Basis and Clinical Perspectives
Jeng-Jiann Chiu et al.
PHYSIOLOGICAL REVIEWS (2011)
Changes in Cytokine Levels During Acute Hyperinsulinemia in Offspring of Type 2 Diabetic Subjects
Eija Ruotsalainen et al.
ATHEROSCLEROSIS (2010)
Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance
V. B. Matthews et al.
DIABETOLOGIA (2010)
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation
Shigeru Kotake et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
Molly M. McFarland-Mancini et al.
JOURNAL OF IMMUNOLOGY (2010)
CREB-Mediated IL-6 Expression Is Required for 15(S)-Hydroxyeicosatetraenoic Acid-Induced Vascular Smooth Muscle Cell Migration
Koteswara R. Chava et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2009)
Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT)
Aramesh Saremi et al.
ATHEROSCLEROSIS (2009)
Interleukin-6 Attenuates Insulin-Mediated Increases in Endothelial Cell Signaling but Augments Skeletal Muscle Insulin Action via Differential Effects on Tumor Necrosis Factor-α Expression
Derek Y. C. Yuen et al.
DIABETES (2009)
Prolonged interleukin-6 administration enhances glucose tolerance and increases skeletal muscle PPARα and UCP2 expression in rats
Anna G. Holmes et al.
JOURNAL OF ENDOCRINOLOGY (2008)
Interleukin-6 regulates pancreatic α-cell mass expansion
Helga Ellingsgaard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Transgenic blockade of interleukin 6 transsignaling abrogates inflammation
Bjorn Rabe et al.
BLOOD (2008)
IL-6 signalling in exercise and disease
B. K. Pedersen
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Mice heterozygous for tumor necrosis factor-α converting enzyme are protected from obesity-induced insulin resistance and diabetes
Matteo Serino et al.
DIABETES (2007)
Mechanisms of induction of endothelial cell E-selectin expression by smooth muscle cells and its inhibition by shear stress
Jeng-Jiann Chiu et al.
BLOOD (2007)
An essential role for gp130 in neointima formation following arterial injury
Dong Wang et al.
CIRCULATION RESEARCH (2007)
Interleukin-6 impairs the insulin signaling pathway, promoting production of nitric oxide in human umbilical vein endothelial cells
Francesco Andreozzi et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Interleukin-6 increases insulin-stimulated glucose disposal in humans and glucose uptake and fatty acid oxidation in vitro via AMP-activated protein kinase
Andrew L. Carey et al.
DIABETES (2006)
The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF alpha receptors
Matthias Canault et al.
ATHEROSCLEROSIS (2006)
IL-6 induces PI 3-kinase and nitric oxide-dependent protection and preserves mitochondrial function in cardiomyocytes
N Smart et al.
CARDIOVASCULAR RESEARCH (2006)
Interleukin-6 and diabetes - The good, the bad, or the indifferent?
OP Kristiansen et al.
DIABETES (2005)
Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-α
M Federici et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Mechanisms of disease - Inflammation, atherosclerosis, and coronary artery disease
GK Hansson
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The IL-6R α chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo
A Doganci et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
Reduced endothelial NO-cGMP-mediated vascular relaxation and hypertension in IL-6-infused pregnant rats
JM Orshal et al.
HYPERTENSION (2004)
Interleukin-6 is a novel factor mediating glucose homeostasis during skeletal muscle contraction
MA Febbraio et al.
DIABETES (2004)
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
PC Heinrich et al.
BIOCHEMICAL JOURNAL (2003)
Hexameric structure and assembly of the interleukin-6/IL-6 α-receptor/gp130 complex
MJ Boulanger et al.
SCIENCE (2003)
Inflammatory cytokines and the risk to develop type 2 diabetes -: Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study
J Spranger et al.
DIABETES (2003)
Differential expression of plasminogen activator inhibitor-1, tumor necrosis factor-α, TNF-α converting enzyme and ADAMTS family members in murine fat territories
G Voros et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION (2003)
Interleukin-6-deficient mice develop mature-onset obesity
V Wallenius et al.
NATURE MEDICINE (2002)
Biologic sequelae of interleukin-6 induced P13-K/Akt signaling in multiple myeloma
T Hideshima et al.
ONCOGENE (2001)
The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation:: An experimental model involving thrombin
V Marin et al.
JOURNAL OF IMMUNOLOGY (2001)
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
AD Pradhan et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses
T Jostock et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6
A Steensberg et al.
JOURNAL OF PHYSIOLOGY-LONDON (2000)
Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques - Potential implications for inflammation and plaque instability
B Schieffer et al.
CIRCULATION (2000)
分享论文
